[{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rilpivirine","moa":"||NNRT","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ ViiV Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ ViiV Healthcare"}]

Find Clinical Drug Pipeline Developments & Deals for Zidovudine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Edurant (rilpivirine) is a HIV-1 specific, nonnucleoside reverse transcriptase inhibitor (NNRTI). It is being evaluated for the treatment of HIV-1 infection in children weighing 10 kg or more.

                          Product Name : Edurant

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 28, 2023

                          Lead Product(s) : Rilpivirine,Abacavir,Zidovudine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : ViiV Healthcare

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          University of Washington

                          Country arrow
                          EPSC
                          Not Confirmed

                          University of Washington

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Zidovudine,Lamivudine

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Undisclosed

                          Sponsor : Clinique des Maladies Infectieuses, Fann | Centre de Santé de Ziguinchor | Johnson & Johnson Innovative Medicine | Merck & Co | National Institute of Allergy and Infectious Diseases

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 09, 2018

                          Lead Product(s) : Zidovudine,Lamivudine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Clinique des Maladies Infectieuses, Fann | Centre de Santé de Ziguinchor | Johnson & Johnson Innovative Medicine | Merck & Co | National Institute of Allergy and Infectious Diseases

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          St Stephen's AIDS Trust

                          Country arrow
                          EPSC
                          Not Confirmed

                          St Stephen's AIDS Trust

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 14, 2016

                          Lead Product(s) : Efavirenz,Tenofovir,Emtricitabine,Lamivudine,Zidovudine,Rifampicin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Viatris | United States Agency for International Development

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Universidad Peruana Cayetano Heredia

                          Country arrow
                          EPSC
                          Not Confirmed

                          Universidad Peruana Cayetano Heredia

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 14, 2016

                          Lead Product(s) : Raltegravir Potassium,Zidovudine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          St Stephen's AIDS Trust

                          Country arrow
                          EPSC
                          Not Confirmed

                          St Stephen's AIDS Trust

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 16, 2015

                          Lead Product(s) : Efavirenz,Tenofovir,Emtricitabine,Lamivudine,Zidovudine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Viatris

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Harvard School of Public Health (HSPH)

                          Country arrow
                          EPSC
                          Not Confirmed

                          Harvard School of Public Health (HSPH)

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Nevirapine,Lopinavir,Ritonavir,Lamivudine,Zidovudine

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase II/ Phase III

                          Sponsor : Ragon Institute of MGH, MIT, Harvard | Brigham and Women's Hospital | Botswana Harvard Health Partnership | University of California, San Diego

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 24, 2015

                          Lead Product(s) : Nevirapine,Lopinavir,Ritonavir,Lamivudine,Zidovudine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Ragon Institute of MGH, MIT, Harvard | Brigham and Women's Hospital | Botswana Harvard Health Partnership | University of California, San Diego

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 06, 2014

                          Lead Product(s) : BILR 355 BS,Lamivudine,Zidovudine,Ritonavir

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 25, 2014

                          Lead Product(s) : Tipranavir,Ritonavir,Delavirdine,Zidovudine,Lamivudine,Stavudine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 25, 2014

                          Lead Product(s) : Tipranavir,Ritonavir,Zidovudine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank